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The classical viral vaccine approaches using inactivated virus or live-attenuated virus have not been successful for some viruses, such as
human immunodeficiency virus or herpes simplex virus. Therefore, new types of vaccines are needed to combat these infections. Replication-
defective mutant viruses are defective for one or more functions that are essential for viral genome replication or synthesis and assembly of viral
particles. These viruses are propagated in complementing cell lines expressing the missing gene product; however, in normal cells, they express
viral gene products but do not replicate to form progeny virions. As vaccines, these mutant viruses have advantages of both classical types of viral
vaccines in being as safe as inactivated virus but expressing viral antigens inside infected cells so that MHC class I and class II presentation can
occur efficiently. Replication-defective viruses have served both as vaccines for the virus itself and as a vector for the expression of heterologous
antigens. The potential advantages and disadvantages of these vaccines are discussed as well as contrasting them with single-cycle mutant virus
vaccines and replicon/amplicon versions of vaccines. Replication-defective viruses have also served as important probes of the host immune
response in helping to define the importance of the first round of infected cells in the host immune response, the mechanisms of activation of
innate immune response, and the role of the complement pathway in humoral immune responses to viruses.
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tions in medical science and public health to date because of
their ability to reduce morbidity and mortality caused by
infectious diseases. The ability to elicit a host immune
response that protects against viral disease has been the
standard for viral vaccines, and this has been successful for
smallpox, poliomyelitis, yellow fever, hepatitis B, influenza,
chickenpox, and a number of other viral diseases. Tradi-
tionally, viral vaccines have been one of two types, the first
being inactivated whole virus particles or viral subunit
proteins while the second is live-attenuated virus. Inactivated
viral vaccines are essentially inert antigens that induce CD4+
T cell and humoral responses while live-attenuated viruses,
which undergo limited replication within the host, elicit
CD8+ and CD4+ cellular as well as humoral immune
responses without causing disease.
The two classical poliovirus vaccines best illustrate these
two different types of vaccines. The inactivated polio vaccine
(IPV) developed by Jonas Salk, consists of whole poliovirus
rendered noninfectious by formaldehyde treatment. The other
polio vaccine, oral polio vaccine (OPV), is a live-attenuated
poliovirus developed by Albert Sabin. While both of the polio
vaccines are very effective at reducing poliomyelitits, there are
advantages and disadvantages to each approach. IPV is very
safe because it contains no live virus, but it must be
introduced by injection and induces no mucosal immunity.
OPV is easily administered to large populations by oral
inoculation, but it can revert to a virulent form of poliovirus
capable of causing disease. Although both vaccines are
effective at preventing disease, only IPV is used now in the
U.S. because of its safety.
Other live-attenuated viral vaccines include vaccines for
yellow fever, measles, Rubella, chickenpox, and hepatitis A.
Other killed virus vaccines include influenza and rabies, while
the hepatitis B vaccine is a subunit vaccine.
However, for some viruses such as human immunodefi-
ciency virus (HIV) or herpes simplex virus (HSV), these
classical approaches to viral vaccines have not been successful.
Thus, new vaccine approaches need to be developed. For AIDS
vaccines, live-attenuated simian immunodeficiency virus (SIV)
has been the only successful approach for immunization
against SIV (Daniel et al., 1992), but there are concerns about
whether a live-attenuated HIV can ever be made safe enough
for widespread immunization of healthy individuals. Mean-
while, subunit vaccines do not induce the CD8+ T cell
responses needed for protection against HIV, so alternative
vaccine approaches are needed. Similarly, it has not been
possible to attenuate herpes simplex virus so that it is safe but
still immunogenic (Koelle and Corey, 2003).
Viruses that persist in the host raise another level of
complexity in terms of vaccine design and implementation.For these viruses, immunization needs to reduce infection to as
low a level as possible, not just prevent primary disease,
because viral infection of the appropriate cells can lead to
establishment of a persistent infection. As with HIV infection
of CD4+ T cells, this could ultimately lead to disease due to
viral persistence and reactivation and disease.
Replication-defective mutant viruses
Replication-defective viral mutant strains provide a new
form of viral vaccine that combines some of the advantages of
each of the two classic vaccine forms. Replication-defective
mutant viruses are specifically defective for viral functions that
are essential for viral genome replication and assembly of
progeny virus particles. They are propagated in complementing
cell lines that express the missing viral gene product(s),
allowing viral replication (Fig. 1, top panel). In contrast, in
normal cells, one or more steps in viral replication are blocked,
resulting in viral gene expression within the infected cell but no
progeny virus production. The tight block in replication for
these mutant viruses makes their high level of safety one of the
main advantages for the use of replication-defective mutant
viruses as vaccines. Probably the first use of replication-
defective viruses as a vaccine for that microbe was the use of
replication-defective HSV-1 strains to protect mice against
HSV-1 infection (Nguyen et al., 1992). At the time of that
publication, it was surprising that a replication-defective
mutant virus could induce protective immunity because it
was generally thought that viral vaccines had to be delivered as
either a replicating virus or a large amount of inactivated viral
antigen to induce a protective immune response (Murphy and
Chanock, 1990). In the study of Nguyen et al. (1992), both
immediate-early and early gene mutant viruses protected mice
against HSV-1 infection. These viruses are absolutely defective
for viral replication, yet the protective immunity is durable for
at least 7 months in mice (Morrison and Knipe, 1996).
Surprisingly, the magnitude and durability of the immune
responses are equal for the replication-defective mutant virus
and its replication-competent parental virus, arguing that the
bulk of the immune responses are generated against viral gene
products expressed in the first round of infected cells (Morrison
and Knipe, 1996). This raised the importance of the first round
of infected cells, presumably including antigen-presenting
cells, in eliciting antiviral immune responses.
Replication-defective mutant viruses provide important
probes in the study of immune response mechanisms as, due
to their replication-defect, their infection is largely restricted to
the site of inoculation. Replication-defective HSV mutant
strains have provided a model system for the study of the role
of complement in immune responses to viral infection at a
peripheral tissue site following intradermal inoculation (Da
Fig. 1. Comparison of replication-defective and single-cycle herpes simplex viruses. Top panel: diagram of the biological properties of a herpes simplex virus
replication-defective mutant strain. Bottom panel: diagram of the biological properties of a herpes simplex virus single-cycle mutant strain.
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pathway has been shown to be essential for humoral responses
to viral infection (Da Costa et al., 1999a, 1999b), and these
complement components are provided by myeloid cells either
in the dermis or in draining lymph nodes (Verschoor et al.,
2001, 2003).
Replication-defective viruses have also been used as vaccine
vectors to express heterologous antigens to induce immune
responses against other microbes. Probably the first use of this
vector approach was a fowlpox recombinant virus expressing
rabies glycoprotein that protected mice, cats, and dogs against
lethal infection by rabies virus (Taylor et al., 1988). A number
of applications of replication-defective viruses as vaccines andvaccine vectors have been reported, and we will discuss the
major advances with these recombinant viruses in this review.
Single-cycle mutant viruses
A somewhat similar but technically different form of viral
vaccine is the single-cycle mutant virus. These mutant viruses
are defective in a virion protein that functions after viral
assembly. The viruses are propagated in complementing cells
that express the missing gene product (Fig. 1, bottom panel). In
normal cells, the replication cycle occurs normally and progeny
virions are produced. However, these virions are noninfectious
so the infection does not spread to a second round of cells. The
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can spread beyond the infected cell; nevertheless, the block in
spread may not be complete for all of these viruses (Loudon et
al., 2001), as discussed below. Thus, there are potential
advantages and disadvantages to the single-cyclemutant viruses.
Amplicon or replicon vaccines
Amplicon or replicon genomes contain the minimal cis-
acting signals for viral genomic replication, an origin of
replication and packaging signals. The viral proteins needed for
genomic replication and virion formation are supplied by a
helper virus or a ‘‘packaging’’ cell line. These defective viruses
have been used mostly as vaccine vectors with the transgene
inserted into the minimal viral genome needed for replication
and packaging into virions.
Replication-defective viruses as vaccines
Herpes simplex virus
Herpes simplex virus 1 and 2 are common human pathogens
that cause mucosal infections and spread to and establish latent
infections in sensory neurons. They later can reactivate to cause
recurrent disease. HSV infections occur throughout life and
present as a variety of clinical syndromes. These include
neonatal HSV infection, HSV orolabialis, herpetic whitlow,
HSV infection of eczematous skin, HSV keratitis, HSV
encephalitis, and HSV genitalis. HSV can also cause severe
disease in the immunocompromised such as those with HIV/
AIDS. The large economic and disease burden caused by HSV
disease and the likely contributory role of genital herpes
infection in the HIV/AIDS pandemic drive the efforts to find an
effective HSV vaccine (Jones and Knipe, 2003). HSV
glycoprotein subunit vaccines have either provided no clinical
protection (Corey et al., 1999) or limited protection in HSV-
seronegative women only (Stanberry et al., 2002), likely
because no HSV-specific CD8+ T cell responses were induced.
A live-attenuated HSV recombinant showed limited immuno-
genicity (reviewed in Koelle and Corey, 2003); thus, new types
of herpes vaccines are needed.
The use of replication-defective HSV as a vaccine
HSV-1 replication-defective mutant viruses were first used to
induce protection in mice against virulent HSV-1 infection
(Morrison and Knipe, 1994; Nguyen et al., 1994). An HSV-2
replication-defective mutant was then used to induce protection
in guinea pigs against HSV-2 infection (Da Costa et al., 1997).
These mutants can infect normal cells and express immediate-
early, early, and some of the late proteins, but are blocked for
DNA synthesis and therefore do not complete the replication
cycle (Fig. 1, top panel).
For increased safety in a newer vaccine virus strain, twoHSV-
2 genes essential for viral DNA synthesis and viral replication,
UL5 andUL29, were deleted from HSV-2 to generate the dl5-29
vaccine candidate virus (Da Costa et al., 1999a, 1999b; Da Costa
et al., 2000).UL5 encodes one of the three known components ofthe viral helicase–primase complex, whileUL29 encodes ICP8,
a single-stranded DNA-binding protein. In a murine infection
model, dl5-29 protects mice against a highly lethal challenge
with wild-type HSV-2 (Da Costa et al., 1999a, 1999b). Recently,
dl5-29 was tested side-by-side with a recombinant HSV-2
glycoprotein D (gD2) subunit vaccine in Freunds’ adjuvant.
Surprisingly, dl5-29 elicits significantly higher neutralizing
antibody titers and increased levels of HSV-2-specific CD8+ T
cells than the gD2 vaccine (Hoshino et al., 2005). This translated
into similar protection as a prophylactic vaccine and stronger
efficacy as a therapeutic vaccine in the guinea pig animal model
system (Hoshino et al., 2005).
The HSV-2 dl5-29 virus also has a defect in establishing
and/or maintaining a latent infection (Da Costa et al., 1999a,
1999b). When inoculated at peripheral sites, very little viral
DNA reaches the ganglion and this viral DNA is rapidly lost
from the ganglia (Da Costa et al., 1999a, 1999b). The lack of
latent infection by this viral strain is an important additional
safety feature of dl5-29. The dl5-29 vaccine is being prepared
currently for clinical trials.
Single-cycle HSV mutants as a vaccine
HSV mutants lacking the glycoprotein H (gH) gene are
grown on complementing cells containing the HSV gH gene
(Fig. 1, bottom panel). The mutant virus can infect normal cells
and undergo a single cycle of replication (Forrester et al.,
1992); thus, these viruses are replication-competent as de-
scribed by Farrell et al. (1994). However, the viruses produced
by this infection are unable to infect the next round of cells.
HSV-1 gH mutants can protect mice against HSV-1 infection in
the ear (Farrell et al., 1994) and guinea pigs against HSV-2
genital infection (McLean et al., 1994). Although the HSV-1
gH mutant virus is considered to be limited to a single cycle,
latent viral infections are detected after in vivo inoculation of
the virus, as evidenced by in situ hybridization detection of the
latency-associated transcript (LAT) expression (Loudon et al.,
2001). Because establishment of latent infection involves
spread from cell to cell, this mutant may be leaky for
replication in vivo. A HSV-2 gH mutant virus was able to
protect guinea pigs when used for immunization either
prophylactically or therapeutically (Boursnell et al., 1997).
Although this virus elicited protective and therapeutic immu-
nity in preclinical animal studies, it failed to show any
therapeutic benefits in a Phase II trial.
Replication-defective poxviruses as smallpox vaccines
Poxviruses are large, enveloped, double-stranded DNA
viruses containing genomes of 130–230 kbp, the prototype
virus being variola major, the causative agent of smallpox.
Efforts at immunization against smallpox have a long and rich
history, and in fact, vaccination in its modern sense began in
1796 when Edward Jenner proved that deliberate inoculation
with cowpox could prevent smallpox. Cowpox virus was used
as a vaccine for smallpox, but over many years of propagation,
the stocks became contaminated with another poxvirus that was
named vaccinia virus. The world-wide eradication of smallpox
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attenuated vaccinia virus as the vaccine. Smallpox vaccination
was stopped in the U.S. in 1972, but concerns about the use of
smallpox virus as a potential agent of bioterrorism and the
emergence of monkeypox in the U.S. (Sejvar et al., 2004) have
regenerated interest in smallpox vaccines. Although vaccinia
virus was effective as a smallpox vaccine, there are concerns
about its safety, because the vaccine strains can cause
disseminated infection in immunocompromised individuals
and individuals with atopic dermatis. In addition, rare cardiac
complications can arise. Thus, new vaccines are being studied.
One of the new smallpox candidates being tested is the
Modified Vaccine Ankara or MVA strain of vaccinia virus,
which was derived by passage in chicken cells (Mayr et al.,
1975). During passage in chicken cells, MVA lost about 15%
of the vaccinia virus genome, including genes needed for
replication in human cells, pathogenicity, and blocking the host
immune response. MVA is effectively replication-defective in
primary human fibroblasts (C. Lee, personal communication).
MVA induces protection against monkeypox in nonhuman
primates (Earl et al., 2004) and protects immunocompetent and
immunodeficient mice against virulent vaccinia virus infection
(Wyatt et al., 2004). Thus, MVA appears to be a safe and
efficacious vaccine candidate against both monkeypox and
smallpox infection.
A replication-defective mutant vaccinia virus, dVV-L, has
also been derived from the highly attenuated Elstree/Lister
strain of vaccinia by deletion of the essential gene encoding the
uracil-DNA-glycosylase enzyme. This deletion renders the
virus completely replication-defective (Holzer and Falkner,
1997). Immunization studies have shown that responses to
dVV-L are comparable to those of MVA and Wyeth strains of
vaccinia (Coulibaly et al., 2005). This mutant may have some
growth and production advantages over MVA or other strains
that grow in primary cells.
Other replication-defective mutants as vaccines
Other replication-defective mutants are also being consid-
ered as vaccines. For example, an influenza NS2-knockout
virus provided protective immunity in mice against a patho-
genic influenza strain (Watanabe et al., 2002). In addition,
immunization of rhesus macaques with genetically engineered,
single-cycle simian immunodeficiency virus mutant virus
reduced viral load after challenge with pathogenic SIVmac239
(Evans et al., 2005).
Replication-defective viruses as vaccine vectors
Poxvirus
The use of fowlpox virus recombinants in mammals was the
first use of a replication-defective vaccine vector (Taylor et al.,
1988). Poxviruses are strong candidates for vaccine vectors
because they grow to high titers, are very stable when
lyophilized, and are capable of accepting large transgene
sequences. The replication-competent strains of poxviruses usedas smallpox vaccines have been used to create vaccine vectors
against homologous pathogens but concerns about their safety
remain.
The avipoxvirus vectors have a good safety profile because
their replication is restricted to avian species, and they are
incapable of replication in mammalian cells. In addition, there
is little no natural immunity against the avipoxviruses found
within humans. These properties make avipoxviruses attractive
replication-defective vaccine vectors.
Two avipoxviruses that have been employed as vaccine
vectors are fowlpox and canarypox. Canarypox has been
shown to be more efficacious within mammalian cells than
fowlpox and has been used to develop vaccines against many
diseases including HIV (Abimiku et al., 1995; Girard et al.,
1995), rabies (Taylor et al., 1991), measles (Taylor et al.,
1992), and malaria (Rogers et al., 2001). Both of these
avipoxviruses have even been studied in human clinical trials,
but CD8+ T cell responses have been disappointing (Konishi et
al., 1998; Marshall et al., 1999).
Modified vaccina virus Ankara (MVA) has been used not
only as a vaccine but also as an effective vaccine vector (Sutter
and Moss, 1992). Effective immune responses have been
elicited using MVA against a variety of pathogens, including
HIV (Amara et al., 2001; Hirsch et al., 1996), influenza (Sutter
et al., 1994), measles (Stittelaar et al., 2000), dengue (Men et
al., 2000), and malaria (Schneider et al., 1998). The ability of
MVA vectors to elicit protective immunity combined with its
safety has brought various MVA vaccine vectors into clinical
trials (reviewed in Drexler et al., 2004).
Adenovirus
Replication-incompetent recombinant adenoviruses are per-
haps the most widely studied and used replication-defective
vaccine vectors. Adenoviruses are nonenveloped, double-
stranded DNA viruses with genomes of approximately 36
kbp. First-generation adenovirus vectors were rendered repli-
cation-defective by deletion of the E1 region of the genome,
which is required for viral replication and gene expression, and
insertion of the transgene expression cassette. Because the E1
functions are not absolutely essential for viral replication, these
vectors were capable of some low-level replication. Further
modifications have been made to abrogate their ability to
replicate, including mutations within the E2A region and/or
deletions of E2a, E3, and/or E4 regions (reviewed in Lai et al.,
2002; Tatsis and Ertl, 2004).
Replication-defective adenovirus vectors are extremely safe,
stable, and easily produced in high titers, can be lyophilized and
administered through various routes, and have a broad host cell
range. They express transgenes to high levels, activate the innate
immune system, and stimulate dendritic cell maturation (Morelli
et al., 2000; Rea et al., 1999; Tan et al., 2005) leading to
elicitation of strong immune responses. Recently, helper-
dependent adenoviral vectors (HdAd) have been examined for
their ability to elicit an immune response. These vectors carry
DNA that only contains the inverted terminal repeats and the
packing signal from adenovirus, each necessary for vector
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to 37 kb (Mitani et al., 1995). The major disadvantages to
adenovirus vectors are that, with the exception of HdAd vectors,
they can only tolerate small heterologous sequences, up to 9 kb,
and preexisting immunity to adenoviruses can dampen the
effectiveness of the vectors (Shiver and Emini, 2004; Xiang et
al., 2002). To overcome preexisting immunity, numerous human
serotypes have been used, as well as nonhuman adenoviruses
(Shiver and Emini, 2004; Tatsis and Ertl, 2004).
Adenovirus recombinants have been used to protect animals
against pathogenic challenge with various pathogens such as
SHIV (Shiver et al., 2002), Ebola (Sullivan et al., 2000), swine
influenza virus (Tang et al., 2002) measles (Schindler et al.,
1994), malaria (Rodrigues et al., 1997), tuberculosis (Bruna-
Romero et al., 2001; Tsuji et al., 1998; Wang et al., 2004), and
anthrax lethal toxin (Tan et al., 2003).
Alphavirus
There is growing use of alphavirus vaccine vectors because
of their broad host cell range, their tropism for dendritic and
monocytic cells (MacDonald and Johnston, 2000; Ryan et al.,
2000), their ability to stimulate innate immune receptors (Saiku
et al., 2003), their high levels of transgene expression, and lack
of preexisting immunity within the human population. Alpha-
viruses are members of the Togaviridae family. They are
enveloped viruses with single-stranded, positive-strand RNA
genomes. The 5V end of the genome encodes the nonstructural
genes, while the 3V end encodes the structural genes. The
nonstructural genes are translated from the genomic RNA after
its release into the cell cytoplasm. These nonstructural proteins
form a replication complex that drives the production of the
negative-stranded anti-genomic RNA and also transcribes the
full-length positive stranded genomic RNA and a shorter
subgenomic RNA. The subgenomic RNA encodes the structural
genes. This arrangement allows for rapid multiplication of
subgenomic mRNA in that as the full genomic RNA is
replicated there are more templates for transcription through
the subgenomic promoter, leading to exponential amplification
of the subgenomic RNA. Alphaviral replicons are created by the
replacement of the structural genes with heterologous genes,
abrogating the virus’ ability to replicate due to the loss of its
structural genes while allowing for extremely high expression
of the transgene (reviewed in Rayner et al., 2002; Schlesinger
and Dubensky, 1999).
Alphaviral replicon vectors are being developed using
Sindbis virus, Semliki Forest virus, and Venezuelan equine
encephalitis virus. These vectors have elicited protective
immunity against a wide variety of pathogens including SHIV
(Berglund et al., 1997), influenza (Pushko et al., 1997), Marburg
virus (Hevey et al., 1998), Ebola (Pushko et al., 2000), measles
(Pan et al., 2005), and malaria (Tsuji et al., 1998).
Herpes simplex virus
HSV makes an attractive vaccine vector in that it is
highly infectious for an extremely broad host cell range,activates the innate immune system through Toll-like
receptors (Kurt-Jones et al., 2004; Lund et al., 2003), can
accommodate large insertions of heterologous DNA at
numerous loci within its genome, can infect and express
antigen within nondividing cells, and produces high titer
stocks. HSV induces a durable immune response, and even
replication-defective mutants induce long-lived immunity
(Morrison and Knipe, 1996).
Vaccination of rhesus macaques with replication-defective
HSV-1 recombinant expressing SIV antigens showed partial
protection against mucosal challenge with the pathogenic
SIVmac239 virus in the vaccinated monkeys (Murphy et al.,
2000). In addition, a mutant HSV-1 deleted for the ICP4,
ICP22, and ICP27 genes and expressing ovalbumin as a model
antigen elicited protection against a lethal challenge with a
recombinant Listeria monocytogenes expressing OVA (Lau-
terbach et al., 2004).
Further improvements in HSV vaccine vectors are recom-
binants deleted for four immediate-early genes, ICP4, ICP22,
ICP27, and ICP47 (Samaniego et al., 1998; Watanabe, D.,
Brockman, M.A., Mathews, L., Ndung’u, T., Pavlakis, G.,
Desrosiers, R., DeLuca, N.A., Knipe, D.M., manuscript in
preparation). Recombinants expressing SIV genes products
are immunogenic in rhesus macaques and induce partial
protection against intravenous challenge with the highly
pathogenic SIVmac239 virus (Kaur, A., Sanford, H., Gerry,
D., Watanabe, D., Lifson, J., Pavlakis, G., Knipe, D.,
Desrosiers, R., manuscript in preparation). Protection against
intravenous challenge with this virus had previously been
achieved only with live-attenuated SIV; therefore, this vector
shows great promise.
Due to the high prevalence of HSV infection within the
human population, a possible drawback to the use of HSV
based vectors is the presence of preexisting anti-HSV
immunity and its potential ability to reduce vector efficacy.
The effect of preexisting immunity on HSV vectors remains
controversial, with some studies showing strong immune
responses in the face of anti-HSV immunity (Brockman and
Knipe, 2002; Hocknell et al., 2002) while another study
showed a reduction in immune responses to a transgene
(Lauterbach et al., 2005).
HSV-derived amplicon systems have been produced to use
as vaccine vectors. In one system, cells are cotransfected with
a BAC containing a packaging signal deleted HSV genome,
needed to create the HSV delivery vehicle, and a HSV
amplicon plasmid, containing the HSV packaging signal and
the transgene of interest (Suter et al., 1999). The resulting
amplicon virus is devoid of any HSV DNA with the
exception of the packaging signal. The amplicon plasmid is
packaged as genome length (152 kb) concatamers, allowing
for high levels of transgene expression in transduced cells
(Geller and Breakefield, 1988; Spaete and Frenkel, 1982).
HSV amplicons expressing HIV gp120 are highly immuno-
genic in mice (Hocknell et al., 2002) and show some
protection of hu/SCID mice challenged with HIV (Gorantla
et al., 2005). Thus far, titers of these amplicon vectors seem
to be limiting for vaccine production.
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Replication-defective vaccine vectors have been produced
with many other viruses, including adeno-associated virus
(AAV), poliovirus, and Sendai virus.
AAV is a small, nonenveloped helper-dependent parvovi-
rus, with a genome of 4.7 kbp. While AAV is commonly
found in humans, it has no known pathology. AAV replication
requires coinfection with a helper virus, such as an
adenovirus or herpes virus. Recombinant AAV (rAAV) is
produced by removal of endogenous viral genes and insertion
of a transgene expression cassette between the inverted
terminal repeats of AAV. This recombinant vector DNA is
transfected into a cell expressing the AAV Rep and Cap
proteins and then helper functions are provided to that cell,
often by superinfection with adenovirus. rAAV expressing
SIV genes has recently been shown to elicit an immune
response that significantly limited the replication of SIV after
a virulent challenge (Johnson et al., 2005).
There is a long history of safety involving the use of a live
poliovirus in humans through vaccination programs with OPV.
This relative safety is further improved by rendering the virus
replication-defective. Poliovirus replicons are produced by
insertion of the transgene into the virion coat protein VP1
capsid gene, transfection of replicon RNA into cells, and
infection of those cells with a helper virus. Replicon RNA is
packaged into the poliovirus particle, rendering an infectious
virus (Moldoveanu et al., 1995). Pig-tailed macaques immu-
nized with poliovirus replicons expressing HIV and SIV
proteins and HIV and SIV recombinant proteins elicited
protective immunity against a lethal pathogenic SHIV chal-
lenge. This protection was above that of recombinant protein
alone (Fultz et al., 2003). Poliovirus replicons have also elicited
protective responses against tetanus toxin in the face of
preexisting immunity (Porter et al., 1997) and have shown
prophylactic and therapeutic efficacy against Helicobacter
pylori (Smythies et al., 2005).
Sendai virus is an enveloped, negative-strand RNA virus
from the Paramyxoviridae family with a genome of approx-
imately 15 kb. A replication-defective Sendai virus has been
produced by deleting the gene encoding the fusion protein (F)
required for viral entry (Li et al., 2000). A DNA prime and SeV
boost this immunization protocol-elicited protection in cyno-
molgous macaques against a pathogenic SHIV challenge
(Takeda et al., 2003).
Perspectives
Replication-defective viruses provide unique forms of viral
vaccines that combine the safety of a killed virus vaccine and the
immunogenicity of a live virus vaccine by expressing gene
products within cells so the antigens can be presented efficiently
by both MHC class I and class II pathways. Replication-
defective viruses can also activate Toll-like receptors and other
innate immune response pathways, thereby serving as their own
adjuvants. In addition, replication-defective viruses can be used
as tools to investigate the workings of the immune system.Studies with these vectors have defined mechanisms of innate
response stimulation, the role of primary infected cells in the
immune response, and the role of complement in the host
immune response. However, there is still much to learn about the
mechanisms of host responses and the interaction between
viruses and the host. Future research on viral vaccines and
vaccine vectors should be directed at gaining a basic under-
standing of the connection between host innate and adaptive
immune responses, how specific viruses activate or inactivate
innate host responses, and how we can minimize the ability of
the virus or viral vector to block the host response while
maximizing its ability to stimulate a protective immune
response. This may include targeting to specific immune cells
such as dendritic cells, stimulation of innate immune receptors
like Toll-like receptors, the induction of type I interferons and
cytokines, and elimination of virus-mediated evasion of these
host responses.
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